 Kintara Therapeutics Inc NASDAQ:KTRA has announced interim data from two Phase 2 clinical trials of its lead compound, VAL-083 for glioblastoma multiforme GBM, which continue to demonstrate its potential as a game-changing treatment option. The data were presented in two posters at the 2021 American Association for Cancer Research AACR annual meeting, which is taking place virtually from April 10 to April 15, 2021. 